Larsen Score at 10 Years (144 Patients) | Annual Progression Rate (221 Patients) | |||
---|---|---|---|---|
p | OR (95% CI) | p | OR (95% CI) | |
Baseline Larsen score | < 0.0001 | 17.123 (7.484–39.178) | < 0.0001 | 2.907 (1.671–5.060) |
Baseline no. of erosive joints | < 0.0001 | 16.242 (7.035–37.498) | 0.008 | 2.180 (1.260–3.774) |
Anti-CCP positivity | < 0.0001 | 4.6 (2.187–9.677) | < 0.0001 | 4.337 (2.382–7.896) |
IgA RF positivity | 0.017 | 2.509 (1.232–5.109) | 0.007 | 2.297 (1.284–4.110) |
IgM RF positivity | 0.03 | 2.212 (1.133–4.317) | < 0.0001 | 2.759 (1.6–4.758) |
Disease duration at baseline | 0.001 | 3.559 (1.77–7.143) | 0.026 | 1.896 (1.11–3.236) |
Rheumatoid nodules | 0.055 | 5.241 (1.072–25.618) | 0.003 | 3.523 (1.554–7.987) |
Time-averaged CRP | 0.004 | 2.8 (1.421–5.515) | < 0.0001 | 3.713 (2.11–6.534) |
Time-averaged ESR | 0.066 | 1.97 (1.013–3.831) | 0.034 | 1.846 (1.081–3.153) |
Time-averaged SJC | 0.066 | 1.97 (1.013–3.831) | 0.007 | 2.549 (1.475–4.404) |
Anti-CCP: anticyclic citrullinated peptide; RF: rheumatoid factor; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SJC: swollen joint count.